Citizens Jmp Reaffirms Market Outperform Rating for Acrivon Therapeutics (NASDAQ:ACRV)

Acrivon Therapeutics (NASDAQ:ACRV – Get Free Report)‘s stock had its “market outperform” rating reissued by analysts at Citizens Jmp in a research report issued on Tuesday, Benzinga reports.

ACRV has been the topic of a number of other research reports. Jefferies Financial Group reaffirmed a “buy” rating on shares of Acrivon Therapeutics in a report on Wednesday, November 11th. Wall Street Zen lowered Acrivon Therapeutics from a “hold” rating to a “sell” rating in a report on Saturday, November 7th. Finally, Weiss Ratings upgraded shares of Acrivon Therapeutics from a “sell (e+)” rating to a “sell (d-)” rating in a research note on Friday, October 9th. Four research analysts have rated the stock with a Buy rating and one has issued a Sell rating to the company’s stock. According to data from MarketBeat.com, Acrivon Therapeutics has a consensus rating of “Moderate Buy” and an average price target of $13.50.

Read Our Latest Report on ACRV

Acrivon Therapeutics Stock Performance

Shares of NASDAQ:ACRV opened at $1.46 on Tuesday. The stock’s 50-day moving average is $1.82 and its 200-day moving average is $1.74. The company has a market cap of $62.56 million, a P/E ratio of -0.78 and a beta of 1.96. Acrivon Therapeutics has a 52-week low of $1.27 and a 52-week high of $3.56.

Acrivon Therapeutics (NASDAQ:ACRV – Get Free Report) last posted its quarterly earnings data on Monday, November 16th. The company reported ($0.42) earnings per share for the quarter, topping the consensus estimate of ($0.44) by $0.02. As a group, equities analysts predict that Acrivon Therapeutics will post -1.71 EPS for the current year.

Insider Buying and Selling

In related news, CEO Peter Blume-Jensen sold 14,036 shares of the firm’s stock in a transaction on Tuesday, August 25th. The stock was sold at an average price of $2.21, for a total value of $31,019.56. Following the completion of the transaction, the chief executive officer directly owned 2,230,052 shares of the company’s stock, valued at $4,928,414.92. This trade represents a 0.63% decrease in their ownership of the stock. The sale was disclosed in a document filed with the Securities & Exchange Commission, which is available through this hyperlink. The sale was made to cover tax withholding obligations related to the vesting of equity awards. Insiders sold 14,843 shares of company stock valued at $32,549 over the last three months. 10.50% of the stock is owned by company insiders.

Hedge Funds Weigh In On Acrivon Therapeutics

A number of hedge funds have recently made changes to their positions in ACRV. Renaissance Technologies LLC lifted its holdings in shares of Acrivon Therapeutics by 19.6% during the 1st quarter. Renaissance Technologies LLC now owns 758,440 shares of the company’s stock worth $1,054,000 after acquiring an additional 124,271 shares during the period. Marshall Wace LLP boosted its position in shares of Acrivon Therapeutics by 2.0% during the 3rd quarter. Marshall Wace LLP now owns 542,344 shares of the company’s stock valued at $1,112,000 after acquiring an additional 10,488 shares in the last quarter. Empowered Funds LLC bought a new stake in Acrivon Therapeutics in the third quarter valued at about $117,000. Spark Investment Management LLC bought a new stake in Acrivon Therapeutics in the second quarter valued at about $50,000. Finally, StoneX Group Inc. bought a new stake in Acrivon Therapeutics in the third quarter valued at about $43,000. Institutional investors and hedge funds own 71.62% of the company’s stock.

Acrivon Therapeutics Company Profile

(Get Free Report)

Acrivon Therapeutics is a clinical-stage biopharmaceutical company developing precision medicines for cancer. Its research focuses on identifying treatments for patients whose tumors have molecular characteristics that may make them more likely to respond to a particular therapy. The company’s Acrivon Predictive Precision Proteomics (AP3) platform analyzes protein activity in tumor samples to identify these characteristics and help guide patient selection. Acrivon’s clinical-stage candidate ACR-368 is a small-molecule inhibitor of the CHK1 and CHK2 enzymes being studied in solid tumors.

Recommended Stories

Analyst Recommendations for Acrivon Therapeutics (NASDAQ:ACRV)

Receive News & Ratings for Acrivon Therapeutics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Acrivon Therapeutics and related companies with MarketBeat.com's FREE daily email newsletter.